ClinicalTrials.gg
RecruitingNCT06819189Updated Nov 10, 2026

Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors

A Phase 1 interventional study of Ethanol in Healthy Volunteer, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA). Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

Background:

Alcohol use disorder (AUD) can damage people s health, work, and family. Researchers want to know more about why some people are more vulnerable to AUD than others. The ZIP8 gene may be linked to an increased risk of AUD. Researchers want to find out how different forms of the ZIP8 gene affect how healthy people drink alcohol and how alcohol affects their brain.

Objective:

To study how genes may affect how people drink alcohol and how it affects their brain.

Eligibility:

Healthy people aged 21 to 60 years. They must not smoke, and they must have no history of AUD. They must have European ancestry and be enrolled in Natural History Protocol (14-AA-0181).

Design:

Participants will have 2 study visits.

At the first visit, participants will be given alcohol; it will be infused through a tube attached to a needle inserted into a vein. They may self-administer each dose by pressing a button. Over time, they will have to press the button an increasing number of times to receive more alcohol. The infusion period will last 2.5 hours.

Participants will have blood samples taken and breath measurments, and they will do computer tasks and complete questionnaires during and after the infusion. After the infusion, they will remain in the clinic until their breath alcohol levels drop to a safe level.

At the second visit, participants will have an imaging scan of their brain. They will do tasks and play games on a computer screen during the scan.

Some participants may have an extra visit for screening. A mid-study visit may also be needed if more than 6 months pass between the 2 study visits.

Read the detailed description

Study Description:

Genome-wide association studies of alcohol use disorder and alcohol consumption phenotypes have consistently identified significant associations with the metal ion transporter ZIP8 gene, specifically a single nucleotide polymorphism SLC39A8. The goal of this study is to examine the effect of SLC39A8 variation on alcohol-related phenotypes using an integrated translational pharmacogenetics approach. Alcohol-seeking and consumption will be evaluated using a human lab model of alcohol self-administration in a sample of 50 male and female non-AUD drinkers, classified into 2 groups based on their SLC39A8 genotype (rs13107325): 1) T-allele carriers (TT or CT genotype), and 2) CC-allele homozygotes (CC genotype). Participants will also undergo resting-state functional MRI scanning to assess functional connectivity in brain networks such as the salience network, and task-based functional MRI scans to assess activation in brain regions associated with reward processing and decision making, for association with SLC39A8 SNP genotype. The hypotheses guiding this project are that SLC39A8 variation would be associated with altered alcohol self-administration phenotypes of alcohol seeking and consumption, as well as with brain activation in brain regions associated with reward and decision making that are also associated with alcohol s effects.

Objectives:

Primary Objective:

To examine the effect of SLC39A8 genetic variation on IV alcohol self-administration phenotypes in non-AUD drinkers.

Secondary Objective:

To examine the effect of SLC39A8 genetic variation on brain activation and responses using functional magnetic resonance imaging in non-AUD drinkers.

Endpoints:

Primary Endpoints:

IV alcohol self-administration measures - Peak breath alcohol concentration (BrAC), number of alcohol infusions received.

Secondary endpoints:

brain activation (fMRI BOLD signal change) associated with reward during the monetary incentive delay (MID) task. Brain activation (fMRI BOLD signal change) is associated with decision making during the alcohol approach avoidance task (AAAT). Brain regions of interest include striatum, insula, cingulate cortex and prefrontal cortex.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Alcohol
03

In context

Lead sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA) is the lead sponsor of 102 studies on the registry; 14 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 9 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • INCLUSION CRITERIA:

    1. Male and female participants between 21-60 years of age. [Based on: identification provided to Clinical Center Admissions office].
    2. Non-smokers with no history of smoking in the past year and not a daily smoker for more than 1 month in their lifetime. [Based on: smoking history questionnaire, Additional History Form]
    3. Participants of European ancestry: the minor T allele of rs13107325, has a frequency of 0.08 in European ancestry, but is almost absent in Asian and African populations (http://www.ensembl.org). Due to the rare occurrence of the T allele and to avoid populations stratification in this small sample-sized study, only participants with self-reported White racial category (European ancestry) will be enrolled in this study.
    4. Inclusion criteria for persons of : Use of adequate method of during the study, if participant is sexually active and is not surgically sterilized. Adequate methods of contraception include abstinence, use of oral contraceptives; use of barrier method of contraceptive; use of an approved IUD or other long-acting reversible contraceptive (LARC); have a male sexual partner who is surgically sterilized; or have exclusively same-sex sexual partner(s). Justification: To minimize the risk of administering alcohol to pregnant persons of childbearing potential, given the known effects of alcohol exposure on fetuses. [Based on: medical history].
    5. Ability to understand the written consent form and willing to sign it. [Based on: consent quiz].

EXCLUSION CRITERIA:

  1. Current history (past 12 months) of major medical illness, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders, or positive hepatitis (A, B antigen, or C), or test. Justification: Many illnesses may alter the neuropsychological effects of alcohol as well as MRI measures. Hepatitis can alter liver function and alcohol pharmacokinetics. HIV infection can alter brain function. [Based on: findings on medical history and physical exam, , laboratory tests].
  2. Current history of psychiatric disorders, including depressive disorder, bipolar disorder, or anxiety disorders. Justification: Concurrent psychopathology can alter brain function and alcohol response. [Based on: SCID interview]
  3. Lifetime history of psychotic disorders, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), or eating disorder. Justification: These disorders can have long-term effects on brain function and alcohol response. [Based on: SCID interview]
  4. Current or lifetime diagnosis of alcohol or substance use disorder. Past mild AUD or past mild SUD with no current symptoms for at least 2 years will not be exclusionary. Justification: History of moderate to severe alcohol or substance use disorder will impact brain function and alcohol response We do not anticipate past mild AUD or SUD in remission for 2+ years would have such impact on brain function and alcohol response. We will examine this in an exploratory analysis. We will also do a follow-up telephone/telehealth visit with these participants to assess any changes in alcohol or substance use or problems related to their participation in the study. [Based on: SCID interview].
  5. Currently seeking treatment for alcohol use disorders. Justification: It would be unethical to administer alcohol to individuals seeking treatment for alcohol problems. Also, this study does not provide treatment for individuals with alcohol use disorder. [Based on: medical history]
  6. Non-drinkers (alcohol-naive individuals or current abstainers) or individuals with no experience drinking 5 or more drinks on one occasion in their lifetime. Justification: It would be unethical to administer alcohol to individuals that do not drink alcohol. [Based on: medical history].
  7. Current or prior history of alcohol-induced flushing reactions, including rapid reddening of the face, rapid heart rate and breathing, and nausea after 1 or 2 drinks. Justification: It would not be safe to administer alcohol to individuals with the highly aversive flushing response to alcohol. [Based on: alcohol flushing questionnaire].
  8. Positive result on urine drug screen or positive breathalyzer during screening visit. Positive urine drug screen or breathalyzer reading during more than 1 study visit will result in participant withdrawal from the study. Justification: Current or recent exposure to alcohol or drugs of abuse could impact brain function and alcohol response. [Based on: laboratory tests and breathalyzer test].
  9. History of significant withdrawal symptoms or presence of clinically significant withdrawal symptoms (Clinical Institute Withdrawal Assessment (CIWA) score > 8) at screening. Justification: Withdrawal symptoms would be indicative of alcohol use disorder, which is already an exclusion criterion. Additionally, withdrawal symptoms would be a major safety concern for participants, and a major confound in the assessment of alcohol response and brain function. [Based on: CIWA assessment].
  10. Medication exclusion criteria: [Based on Medical history and physical exam, Additional History Form].

    • Use of prescription or OTC medication known to interact with alcohol 2 weeks prior to screening or screening update visit. These include but may not be limited to: isosorbide; nitroglycerine; benzodiazepines; warfarin; anti-depressants such as amitriptyline, clomipramine and nefazodone; anti-diabetes medications such as glyburide, metformin and tolbutamide; H2-antagonists for heartburn such as famotidine, cimetidine and ranitidine; muscle relaxants; anti-epileptics including phenytoin and phenobarbital; codeine and opioid analgesics including Darvocet, Percocet and hydrocodone.
    • Regular (more than once a week) or prescribed use of antihistamines, pain medicines, and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib, and naproxen, and unable to refrain from these medications for 48 hours prior to study visits.NOTE: Seasonal use of antihistamines is not-exclusionary unless participants are unable to refrain from these medications for

      48 hours prior to study visits.

    • Use of medications known to inhibit or induce enzymes that metabolize alcohol for 4 weeks prior to screening or screening update visit. These include chlorzoxazone, isoniazid, metronidazole, and disulfiram.
    • Use of drugs known to affect hemodynamic response 2 weeks prior to screening or screening update visit. These include antihypertensives, insulin, and thyroid medications.
  11. Exclusion criteria for MRI:

    • Left-handedness (Edinburgh Handedness Scale). Justification: To avoid lateralized effects on brain function measures and reduce potential variance in MRI signals.
    • Presence of ferromagnetic objects in the body that are for MRI of the head (including but not limited to pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments).
    • Fear of enclosed spaces. Justification: To minimize risk and discomfort.
    • Inability to lie comfortably on back for up to 2 hours in the MRI scanner. Justification: To minimize risk and discomfort.

    [Based on: MRI Safety Screening Questionnaire, Additional History Form]

  12. Exclusion criteria for persons of childbearing potential:

Justification: To minimize the risk of administering alcohol to pregnant or nursing persons, given the known effects of alcohol exposure on fetuses and infants.

  • Pregnant [Based on: urine beta-hCG test at screening]. Persons of childbearing potential must also test negative on urine beta-hCG test at the start of every study visit.
  • Breast-feeding [Based on: Medical history and physical exam].
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    IV Ethanol

    IV Ethanol

    Drug: Ethanol

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Endpoints: IV alcohol self-administration measures - Peak breath alcohol concentration (BrAC), number of alcohol infusions received.

    The Peak BrAC and number of infusions are direct measures of alcohol exposure and amount consumed during the laboratory session.

    Time frame: 2 YEARS

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2025
First posted
Feb 11, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
7 updates, last Nov 10, 2026
Show all 7 updates
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 27, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date
  6. Oct 19, 2026
    Minor edits only
    + 1 other change: description
  7. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06819189
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Jun 10, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Vijay A Ramchandani, Ph.D.
Contact
vijayr@mail.nih.gov
(301) 402-8527
Vijay A Ramchandani, Ph.D.
principal investigator · National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethanol

Start the discussion